

*CLAIM AMENDMENTS*

Claims 1-14 (Cancelled).

15. (New) A process for providing a human with a therapeutic protein comprising: introducing human cells into a human, said human cells having been treated *in vitro* to insert therein a DNA segment encoding a therapeutic protein, said human cells expressing *in vivo* in said human a therapeutically effective amount of said therapeutic protein, wherein said therapeutic protein is a cytokine other than TNE.

16. (New) The process of claim 15 wherein the cells are blood cells.

17. (New) The process of claim 15 wherein the cells are leukocytes.

18. (New) The process of claim 15 wherein the cells are lymphocytes.

19. (New) The process of claim 15 wherein the cells are T-lymphocytes.

20. (New) The process of claim 15 wherein the cells are tumor-infiltrating lymphocytes (TIL).

21. (New) The process of claim 15 wherein the cells are B-lymphocytes.

22. (New) The process of claim 15 wherein the cytokine is an interleukin.

23. (New) The process of claim 15 wherein the cytokine is granulocyte macrophage colony stimulating factor.

24. (New) The process of claim 15 wherein the cytokine is an interferon.

25. (New) The process of any one of claims 15-24 wherein the DNA segment has been inserted into said cells *in vitro* by a viral vector.

26. (New) The process of claim 25 wherein the viral vector is a retroviral vector.

27. (New) A process for providing a human with a therapeutic protein comprising: introducing human B-lymphocytes into a human, said human B-lymphocytes having been treated *in vitro* to insert therein a DNA segment encoding a therapeutic protein, said human B-lymphocytes expressing *in vivo* in said human a therapeutically effective amount of said therapeutic protein.

28. (New) The process of claim 27 wherein the DNA segment has been inserted into the cells *in vitro* by a viral vector.

29. (New) The process of claim 28 wherein the viral vector is a retroviral vector.